Seer (SEER) Stock Price, News & Analysis

Company Overview

Seer, Inc. (NASDAQ: SEER) is a life sciences company focused on next-generation proteomics, offering a platform that enables comprehensive, high-throughput analysis of proteins at scale. Founded in 2016 and headquartered in South San Francisco, Seer’s mission is to transform biomarker discovery and therapeutic development by revealing unprecedented proteome-level insights. The company’s proprietary technology integrates nanoparticle-based sample preparation with advanced mass spectrometry workflows, delivering deep proteome coverage across diverse biological samples.

The centerpiece of Seer’s offering is the Proteograph Product Suite, which combines magnetic nanoparticle reagents, automated sample processing, and data analysis software to streamline proteomics studies. This end-to-end solution supports large-scale experiments in pharmaceutical and biotechnology research, enabling clients to identify and quantify thousands of proteins in plasma, serum, and other complex matrices. By reducing hands-on time and enhancing reproducibility, the Proteograph Suite accelerates discovery and validation of novel biomarkers and therapeutic targets.

Seer’s platform has been adopted by leading academic institutions, contract research organizations, and biopharmaceutical companies across North America, Europe, and Asia. The company maintains a global network of distribution partners and provides technical support for deployment and method optimization. Strategic collaborations with mass spectrometry instrument manufacturers and bioinformatics firms further extend Seer’s reach and integration into existing proteomics workflows, fostering a growing community of users advancing precision medicine research.

Led by a management team with deep expertise in life-science instrumentation, proteomics, and computational analysis, Seer continues to expand its technological capabilities and application portfolio. With a strong foundation in nanoparticle chemistry and systems engineering, the company is well-positioned to address emerging needs in personalized healthcare and translational research. Seer’s ongoing innovation aims to unlock new dimensions of the proteome, paving the way for improved diagnostics and targeted therapies.

Key Stats

• Today's Range: $2.18 to $2.27
• 50-Day Range: $1.85 to $2.28
• 52-Week Range: $1.56 to $2.63
• Volume: 103,837 shs
• Average Volume: 278,846 shs
• Market Capitalization: $127.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Seer Stock Analysis - MarketRank™

Seer scored higher than 42% of companies evaluated by MarketBeat, and ranked 634th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Seer has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Seer has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Seer are expected to decrease in the coming year, from ($1.42) to ($1.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Seer is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Seer is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Seer has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.55% of the float of Seer has been sold short.

Short Interest Ratio / Days to Cover

Seer has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Seer has recently decreased by 0.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Seer does not currently pay a dividend.

Dividend Growth

Seer does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.55% of the float of Seer has been sold short.

Short Interest Ratio / Days to Cover

Seer has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Seer has recently decreased by 0.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.17

News Sentiment

Seer has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Seer this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for SEER on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Seer insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,926.00 in company stock.

Percentage Held by Insiders

11.28% of the stock of Seer is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.20% of the stock of Seer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SEER Stock Analysis - Frequently Asked Questions

How have SEER shares performed this year?

Seer's stock was trading at $2.31 on January 1st, 2025. Since then, SEER shares have decreased by 6.1% and is now trading at $2.17.

How were Seer's earnings last quarter?

Seer, Inc. (NASDAQ:SEER) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. The firm earned $4.21 million during the quarter, compared to analyst estimates of $3.25 million. Seer had a negative trailing twelve-month return on equity of 24.69% and a negative net margin of 560.90%.
Read the conference call transcript.

When did Seer IPO?

Seer (SEER) raised $150 million in an initial public offering on Friday, December 4th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities and Cowen acted as the underwriters for the IPO.

How do I buy shares of Seer?

Shares of SEER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Seer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Seer investors own include fuboTV (FUBO), NIO (NIO), Advanced Micro Devices (AMD), Peloton Interactive (PTON), Tesla (TSLA) and Lemonade (LMND).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:SEER
• CIK: 1726445
• Web: www.seer.bio
• Phone: 650-453-0000
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +38.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.60 million
• Net Margins: -560.90%
• Pretax Margin: -559.60%
• Return on Equity: -24.69%
• Return on Assets: -22.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.34
• Quick Ratio: 18.81

Sales & Book Value

• Annual Sales: $14.17 million
• Price / Sales: 9.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.54 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 58,870,000
• Free Float: 52,229,000
• Market Cap: $127.75 million
• Optionable: Optionable
• Beta: 1.57